$BRSF Brings Cutting-Edge Tech to the Neurology Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”

To view the full article, visit: https://ibn.fm/feZf8

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.